DSIJ Mindshare

Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends
Kaustubh Bhosale
/ Categories: Trending, Mindshare

Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends

The company has also announced dividends of Rs 3.5 per share that have a face value of Rs 2 per share with a record date fixed on August 22.

The shares of Natco Pharma are likely to be in high demand on Wednesday as the company has announced an extraordinary set of numbers in Q1. The PAT declared is at Rs 320 crore vs Rs 75 crore during a similar period the previous year.   

The company has also announced dividends of Rs 3.5 per share that have a face value of Rs 2 per share with a record date fixed on August 22.   

 

The shares of Natco Pharma have been outperforming markets in the past one month by recording gains of over 18 per cent. BSE Sensex climbed nearly 9 per cent in a similar period.   

Owing to the bumper results and the dividend announcement, the shares of Natco Pharma may remain in the limelight on Wednesday.   

 

The financial trend has been weak for Natco Pharma until the quarter and hence, the positive results in Q1 may attract buyers in the coming sessions.  

 

Hyderabad-based Natco Pharma is a multinational pharmaceutical firm in India. The business produces agricultural health science products, completed dosage formulations of active medicinal components, and contract manufacturing services.  

Previous Article Top-performing pharma stocks in July 2022
Next Article Rs 1 lakh invested in these stocks could have returned up to Rs 15 lakh in one year!
Print
22702 Rate this article:
4.2

2 comments on article "Watch out on Wednesday for this pharma stock that announced bumper Q1 results and 175 per cent dividends"

Avatar image

Ramesh Mohta

How does it went into reverse gear in spite of such a good result.


Avatar image

Laxmi Giri

Can't trust stocks or results anymore I guess..fell more than 10 percent even after such good results. None of the strategy worked here.

Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR